β1 Integrin: Critical Path to Antiangiogenic Therapy Resistance and Beyond

Arman Jahangiri1, Manish K. Aghi1, and W. Shawn Carbonell2

Abstract
Angiogenesis is an important tissue-level program supporting the growth of highly aggressive cancers and early-stage metastases. However, rapid emergence of resistance to antiangiogenic therapies, such as bevacizumab, greatly limits the clinical utility of these promising approaches. The mechanisms of resistance to antiangiogenic therapy remain incompletely understood. The tumor microenvironment has been demonstrated to be a source of broad therapeutic resistance in multiple cancers. Much of the interaction between the cells comprising a tumor and their microenvironment is driven by integrins. Notably, signaling downstream of integrins in tumor cells promotes fundamental programs vital to aggressive cancer biology, including proliferation, growth, invasion, and survival signaling. These functions then can contribute to malignant phenotypes, including metastasis, therapy resistance, epithelial-to-mesenchymal transition, and angiogenesis. Accordingly, we found β1 integrin to be functionally upregulated in tumor specimens from patients after bevacizumab failure and in xenograft models of bevacizumab resistance. Inhibition of β1 in tumor cells with stable gene knockdown or treatment with OS2966, a neutralizing β1 integrin monoclonal antibody, attenuated aggressive tumor phenotypes in vitro and blocked growth of bevacizumab-resistant tumor xenografts in vivo. Thus, β1 integrins promote resistance to antiangiogenic therapy through potentiation of multiple malignant programs facilitated by interactions with the tumor microenvironment. The elucidation of this mechanism creates an outstanding opportunity for improving patient outcomes in cancer. Cancer Res; 74(1); 3–7. ©2013 AACR.

Introduction
Aggressive cancers require adequate vasculature to support continued tumor progression. Tumor vasculature can be derived from preexisting host blood vessels (vessel cooption) or through new vessel growth (angiogenesis). There is likely to be a spectrum of vessel utilization along this continuum depending on various contexts (1). The recognition of the critical importance of vascularization in cancer progression has led to the hope for a new standard of care through the development of antiangiogenic agents such as bevacizumab. However, these drugs, mostly focused on the VEGF pathway, have not produced the clinical outcomes expected on the basis of the dramatic preclinical results in mice. This was most recently demonstrated in a randomized phase III trial in patients with newly diagnosed glioblastoma (2). The reasons for the disparity between preclinical and clinical results with this therapeutic modality are multiple; however, the use of animal models, which themselves rely heavily upon angiogenesis for growth, such as subcutaneous cell line–derived xenografts, likely represents a selection bias for highly angiogenic, VEGF-dependent tumors.

Integrins and Their Role in Cellular Interaction with the Microenvironment in Inflammation and Cancer
Although angiogenesis during wound healing is tightly regulated and self-limiting, angiogenesis associated with chronic inflammation and cancer is often persistent and abnormal. However, many of the molecules that regulate angiogenesis in wound healing, such as integrin αvβ3, also regulate pathologic angiogenesis associated with chronic inflammation and cancer. Increasing evidence points to causative links between inflammation and cancer and suggests that inflammation promotes the angiogenic switch in tumors (3).

This connection between inflammation and cancer underscores the complexity of tumorigenesis and the fact that models that define cancer as driven primarily by a minor population of genetically aberrant cells violates the basic notions of systems biology, evolution, and pathophysiology. Cancer is a systems-level process defined by growth of malignant cells in an organ, which breaches normal tissue boundaries established by the basement membrane. In other words, cancer requires tumor cells directly interacting with cellular and structural components of the surrounding stroma. Dolberg and Bissell demonstrated the importance of this "tumor microenvironment" when they studied cells infected with...
with the rous sarcoma virus (4). In vitro and in early embryonic-stage eggs, the cells grew aggressively. However, when transplanted into late-stage eggs, the genetically malignant program was overridden by the microenvironmental context and the cells incorporated into normal tissue.

Integrins are a major mediator of these interactions between the cells comprising a tumor and their microenvironment. The cells engaging in these interactions include monocytes, in which intratumoral trafficking and subsequent promotion of angiogenesis are mediated by integrin αvβ3 (VLA4; ref. 5). Integrins also contribute to macrophage polarization, with β3 integrin promoting the M1 cytotoxic immunostimulating macrophage phenotype rather than the M2 immunosuppressive, proinvasive phenotype (6). For tumor cells, these interactions with the microenvironment are crucial to the development of malignant features, with reversion of the malignant phenotype demonstrated in breast cancer cells by inhibition of β1 integrin in culture and in vivo (7). These findings emphasize the importance of interactions between the cells comprising a tumor with microenvironmental integrin ligands in the extracellular matrix for tumor progression. Integrins are also crucial to VEGF-dependent and VEGF-independent angiogenesis. On endothelial cells, reciprocal interactions between integrin αvβ3 and VEGFR2 are particularly important during tumor vascularization (8). The αv integrin expression on endothelial cells is also stimulated by VEGF-independent angiogenic growth factors such as bFGF, TNF-α, and interleukin (IL)-8 (9). Finally, mesenchymal aspects of angiogenesis, including endothelial cell invasion and vascular remodeling, rely on α5β1 integrin (10).

We now understand the multiple parallel signaling pathways downstream of integrin engagement that promote tumor growth, including FAK, ERK/MAP kinase, Src, Akt, and Ras (11–14). These pathways are upregulated as β1 levels increase. Indeed, several studies have demonstrated the expression of β1 integrin to correlate with malignant features, including metastasis (15–17). Accordingly, β1 integrin signaling in tumor cells has been shown to promote resistance to multiple treatment modalities, including cytotoxic drugs, radiotherapy (18), targeted therapies such as trastuzumab (19) and lapatinib (20), and oncolytic viruses (21).

β1 Integrin and Resistance to Antiangiogenic Therapy

Rubenstein and colleagues demonstrated that treatment of experimental glioma xenografts with bevacizumab increased invasiveness of tumor cells into normal adjacent brain parenchyma via vessel cooption (22). Nearly a decade later, similar observations were made by Paez-Ribes and colleagues, including increased metastasis (23). These findings can be understood in the context of the vascularization continuum (Fig. 1). In the face of VEGF neutralization and inhibition of neovascularization via angiogenesis, tumor cells must adapt by becoming motile and hijacking the existing vasculature to survive and grow. As part of this invasive process, some cells may intravasate and enter the bloodstream, which may explain the findings of increased metastasis in many studies (15, 16, 23). Importantly, β1 integrins have been recognized to play a major role in metastases (17, 23), tumor growth (24, 25), and invasion (26). Furthermore, Carbonell and colleagues recently identified the β1 integrin–dependent mechanism of vessel cooption driven by adhesion to the vascular basement membrane (27). Vessel cooption provides an instant vasculature for newly metastatic or locally invasive cancer cells. Thus, resistance to antiangiogenic therapy can be explained by cellular stress triggering the Darwinian survival imperative facilitated by enhanced β1 integrin activities. We therefore explored the hypothesis that resistance to antiangiogenic agents such as bevacizumab is promoted by the spectrum of malignant features driven by β1 integrin signaling through interactions with the tumor microenvironment.

We have previously reported diverging radiologic morphology in bevacizumab-resistant glioblastomas (BRG). Some BRGs show a nonenhancing infiltrating pattern, which we found to have upregulated levels of β1 integrin when analyzed with microarray and PCR (28). These results were further validated with immunohistochemistry, which demonstrated increased staining for β1 integrin in bevacizumab-resistant patient specimens, when matched with their respective pre–bevacizumab-treated specimens. Furthermore, flow cytometry of cells from the same bevacizumab-resistant tumors also showed increased levels of β1 integrin in primary cultures compared with cells from bevacizumab-naïve glioblastomas. These findings were replicated in our uniquely developed U87MG cell line–derived xenograft model of bevacizumab resistance.

Because integrin signaling reflects integrin turnover in focal adhesions, we supplemented our static assays of β1 integrin expression with dynamic assessment of β1 integrin turnover. By engineering bevacizumab-resistant and -naïve cell lines to express the β1 integrin–GFP fusion protein, we were able to apply fluorescence recovery after photobleaching to quantify the rate of integrin turnover in the focal adhesions formed. Complementary to our findings above, β1 integrin turnover as well as mobility was increased in the BRGs when compared with the naïve control cell lines. Cell adhesion assays further demonstrated this phenomenon when BRG cell lines showed increased adhesion to the extracellular matrix as compared with the naïve cell lines. Our findings therefore support the functional upregulation of β1 integrin in glioblastomas that evolve to become resistant to antiangiogenic therapy.

We found increased hypoxia in our BRG patient samples compared with their paired naïve samples, which directly correlated with the increased β1 integrin in the BRGs. In vitro studies of U87MGs and two non–central nervous system carcinoma cell lines, HT-1080 and MDA-MB-231, supported this finding with a significant increase in the expression of β1 integrin following hypoxia, suggesting a conserved survival mechanism. The hypoxia that results from antiangiogenic therapy with bevacizumab therefore may play a major role in β1 integrin upregulation.

The role for β1 integrin in the aggressive mesenchymal phenotype of BRGs was further characterized by allowing bevacizumab-resistant cell lines to express short hairpin RNA (shRNA)-targeting β1 integrin (shBETA1) in vitro. This
led to a more epithelioid morphology with increased cell size in shBETA1 clones. Functionally, these cells lacked mesenchymal characteristics, as shown by static and dynamic in vitro assays demonstrating decreased adhesion, cell spreading, and migration. Furthermore, the knockdown cells displayed reduced in vitro proliferation. Spheroid formation in acidic media, a vital adaptive response used by tumor cells, was attenuated in U87-shBETA1 and BRG-shBETA1 cells compared with controls. Inhibiting glioma cells with OS2966 in vitro had similar outcomes as the knockdown in all of the above assays.

We then established preclinical proof-of-concept for the critical role of β1 integrin in BRGs in multiple xenograft models. Systemic treatment of subcutaneous BRG-derived xenografts with two different doses of OS2966 led to significantly smaller tumors than placebo. This treatment also proved effective in orthotopic BRG-derived xenografts. Full-dose combination therapy with bevacizumab and OS2966 led to cutaneous ulceration of 100% of U87MG subcutaneous xenografts, suggestive of synergy. We then alternated low-dose (1 mg/kg) bevacizumab and OS2966 and compared it with the standard dose of 10 mg/kg of bevacizumab alone. The combination therapy proved equally effective, with similar rates of complete regression in both groups. This may help reduce the morbidity of antiangiogenic approaches.

In sum, we have established that β1 integrin is a critical driving force in therapeutic resistance and is a potentially promising adjunctive target in combination with antiangiogenic therapies such as bevacizumab. Thus, targeting β1 integrins holds outstanding potential for improving patient outcomes in glioblastoma.

Current Challenges and Limitations of Targeting β1 Integrin

Successful pharmacologic targeting of β1 integrin will require the development of specialized molecular inhibitors or humanized monoclonal antibodies. Although the ubiquitous cellular expression of integrins may raise concerns about the safety of this approach, chronic administration of up to 20 mg/kg hamster anti-mouse β1 integrin to nude mice resulted in no observable toxicity for up to 4 weeks (7). Accordingly, OS2966, a first-in-class, ligand-selective, humanized and deimmunized neutralizing β1 integrin monoclonal antibody, is currently under development for clinical testing.

In the case of glioblastoma, if penetration of β1 integrin blocking antibodies through the blood–brain barrier (BBB)
after parenteral administration proved suboptimal, intratumoral delivery through strategies such as convection-enhanced or selective endovascular delivery could be considered as well. However, we have also shown in pilot studies that systemically delivered OS2966 successfully targets orthotopic U87 xenografts through the BBB (A. Jahangiri and M. Aghi; unpublished data).

Implications and Future Directions

Our findings underscore the importance of β1 integrin in resistance to antiangiogenic therapy and are part of an emerging literature showing the importance of β1 integrin in the evolution of tumor resistance to multiple therapeutic modalities (18–20). This is consistent with the ability of β1 integrin to stimulate invasion and proliferation and its central role in engaging the microenvironment owing to its ability to bind multiple extracellular matrix and cell adhesion molecules.

Future work will need to identify more detailed mechanisms by which β1 integrin is upregulated during therapeutic resistance. These mechanisms could be transcriptional or post-translational, and regulators could include hypoxia or the VEGF depletion caused by antiangiogenic therapy. It will also need to be determined which α heterodimer partners and respective ligands (23) are important for β1 integrin-mediated therapeutic resistance and to what extent endogenous integrin modulators contribute to the witnessed therapeutic resistance.

On the basis of the prior literature, it is likely the relevance of these findings are much broader than those described in the present study. Our BRG primary and cell lines were derived from patient tumors that failed standard therapy with temozolomide and radiation, as well as bevacizumab. Thus, the present studies are likely relevant to multiple therapies and may represent a clinically predictive model. These results also raise the possibility that other angiogenic cancers, such as breast and colon, may benefit from the addition of anti-β1 integrin strategies to antiangiogenic therapy. This may particularly create a new opportunity for such agents in metastatic breast cancer considering the recent revocation of accelerated approval of bevacizumab in these patients.

In conclusion, very few candidate molecules have been demonstrated to be a critical gatekeeper for nearly all components of the "Hallmarks of Cancer" as β1 integrin (29). From its fundamental role in tumorigenesis, angiogenesis, exponential growth, survival in the face of various therapeutic regimens and cellular stresses, mesenchymal phenotypes, and local invasion and metastasis, targeting β1 integrin has the potential to significantly improve outcomes for patients with cancer.

Disclosure of Potential Conflicts of Interest

M.K. Aghi is a consultant/advisory board member of OncoMed, W.S. Carbonell is the President and CEO of OncoMed, Inc. for which he also has ownership interest (including patents). No potential conflicts of interest were disclosed by the other author.

Authors’ Contributions

Conception and design: A. Jahangiri, M.K. Aghi, W.S. Carbonell

Acquisition of data (provided animals, collected patient data, provided facilities, etc.): M.K. Aghi

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W.S. Carbonell

Writing, review, and/or revision of the manuscript: A. Jahangiri, M.K. Aghi, W.S. Carbonell

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A. Jahangiri, W.S. Carbonell

Received June 18, 2013; revised September 15, 2013; accepted September 16, 2013; published OnlineFirst December 10, 2013.

References


\(\beta_1\) Integrin: Critical Path to Antiangiogenic Therapy Resistance and Beyond

Arman Jahangiri, Manish K. Aghi and W. Shawn Carbonell


**Updated version**

Access the most recent version of this article at:

doi:10.1158/0008-5472.CAN-13-1742

**Cited articles**

This article cites 28 articles, 11 of which you can access for free at:

http://cancerres.aacrjournals.org/content/74/1/3.full.html#ref-list-1

**Citing articles**

This article has been cited by 4 HighWire-hosted articles. Access the articles at:

/content/74/1/3.full.html#related-urls

**E-mail alerts**

Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.